Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099170 | 0.91 | NPSR1 (0.60) | NPSR1NPC1MAPTLMNAKDM4E | |
| SCHEMBL17461866 | 0.82 | NPC1 (0.64) | NPC1MAPTLMNAKDM4EHPGD | |
| SCHEMBL15848966 | 0.79 | HPGD (0.67) | NPC1MAPTLMNAKDM4EHPGD | |
| SCHEMBL7726215 | 0.78 | NPSR1 (0.86) | NPSR1NPC1MAPTLMNAKDM4E | |
| SCHEMBL17461841 | 0.78 | HPGD (0.57) | NPC1MAPTLMNAKDM4EHPGD | |
| SCHEMBL17461867 | 0.78 | HPGD (0.51) | NPSR1NPC1MAPTLMNAKDM4E | |
| SCHEMBL17461833 | 0.78 | NPC1 (0.59) | NPC1MAPTLMNAKDM4EHPGD | |
| SCHEMBL17461825 | 0.74 | HPGD (0.53) | NPC1MAPTLMNAKDM4EHPGD | |
| SCHEMBL17461839 | 0.74 | HPGD (0.53) | NPC1MAPTLMNAKDM4EHPGD | |
| SCHEMBL16099050 | 0.74 | HPGD (0.76) | NPC1MAPTLMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024083-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | AR, KLK3, BRDT | NPSR1 1403/4885NPC1 2157/4885MAPT 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.